Upadacitinib (Rinvoq) is now approved for children aged 2 years and older with active polyarticular juvenile idiopathic arthritis (pJIA) and psoriatic arthritis (PsA) who do not respond well to tumor necrosis factor (TNF) blockers. The drug is available in both tablet and oral solution forms. JIA affects many children in the US, and upadacitinib offers a new treatment option. The drug’s safety profile in pediatric patients is similar to that in adults, with potential risks including serious infections, cancer, blood clots, and allergic reactions. Upadacitinib is also being studied for various other immune-mediated inflammatory diseases in children and adults.
Source link
FDA Extends Upadacitinib Indications to Kids With Arthritis
